254 related articles for article (PubMed ID: 31443436)
21. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?
Bernstein CN; Blanchard JF; Metge C; Yogendran M
Am J Gastroenterol; 2003 Dec; 98(12):2784-8. PubMed ID: 14687833
[TBL] [Abstract][Full Text] [Related]
22. Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease.
Yashiro M
Dig Dis Sci; 2015 Aug; 60(8):2251-63. PubMed ID: 25840920
[TBL] [Abstract][Full Text] [Related]
23. The therapeutic potential of carbon monoxide for inflammatory bowel disease.
Takagi T; Uchiyama K; Naito Y
Digestion; 2015; 91(1):13-8. PubMed ID: 25632911
[TBL] [Abstract][Full Text] [Related]
24. Mucins in inflammatory bowel diseases and colorectal cancer.
Sheng YH; Hasnain SZ; Florin TH; McGuckin MA
J Gastroenterol Hepatol; 2012 Jan; 27(1):28-38. PubMed ID: 21913981
[TBL] [Abstract][Full Text] [Related]
25. Colorectal cancer in inflammatory bowel disease: review of the evidence.
Keller DS; Windsor A; Cohen R; Chand M
Tech Coloproctol; 2019 Jan; 23(1):3-13. PubMed ID: 30701345
[TBL] [Abstract][Full Text] [Related]
26. Clinical features of bowel disease in patients aged <50 years in primary care: a large case-control study.
Stapley SA; Rubin GP; Alsina D; Shephard EA; Rutter MD; Hamilton WT
Br J Gen Pract; 2017 May; 67(658):e336-e344. PubMed ID: 28347985
[TBL] [Abstract][Full Text] [Related]
27. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
Terdiman JP; Steinbuch M; Blumentals WA; Ullman TA; Rubin DT
Inflamm Bowel Dis; 2007 Apr; 13(4):367-71. PubMed ID: 17206695
[TBL] [Abstract][Full Text] [Related]
28. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease.
Söderlund S; Brandt L; Lapidus A; Karlén P; Broström O; Löfberg R; Ekbom A; Askling J
Gastroenterology; 2009 May; 136(5):1561-7; quiz 1818-9. PubMed ID: 19422077
[TBL] [Abstract][Full Text] [Related]
29. Nutraceuticals in rodent models as potential treatments for human Inflammatory Bowel Disease.
Ghattamaneni NKR; Panchal SK; Brown L
Pharmacol Res; 2018 Jun; 132():99-107. PubMed ID: 29680446
[TBL] [Abstract][Full Text] [Related]
30. Ruthenium-based nitric oxide-donating and carbon monoxide-donating molecules.
Pauwels B; Boydens C; Vanden Daele L; Van de Voorde J
J Pharm Pharmacol; 2016 Mar; 68(3):293-304. PubMed ID: 26773555
[TBL] [Abstract][Full Text] [Related]
31. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
32. The therapeutic impact of manipulating microbiota in inflammatory bowel disease.
Kanauchi O; Mitsuyama K; Andoh A
Curr Pharm Des; 2009; 15(18):2074-86. PubMed ID: 19519445
[TBL] [Abstract][Full Text] [Related]
33. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease.
Munkholm P
Aliment Pharmacol Ther; 2003 Sep; 18 Suppl 2():1-5. PubMed ID: 12950413
[TBL] [Abstract][Full Text] [Related]
34. DNA hypermethylation in colorectal neoplasms and inflammatory bowel disease: a mini review.
Maeda O; Ando T; Watanabe O; Ishiguro K; Ohmiya N; Niwa Y; Goto H
Inflammopharmacology; 2006 Dec; 14(5-6):204-6. PubMed ID: 17093903
[TBL] [Abstract][Full Text] [Related]
35. Animal models of carcinogenesis in inflamed colorectum: potential use in chemoprevention study.
Tanaka T
Curr Drug Targets; 2012 Dec; 13(14):1689-97. PubMed ID: 23140280
[TBL] [Abstract][Full Text] [Related]
36. NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease.
Perera AP; Kunde D; Eri R
Curr Pharm Des; 2017; 23(16):2321-2327. PubMed ID: 28155620
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological insights into antioxidants against colorectal cancer: A detailed review of the possible mechanisms.
Gothai S; Muniandy K; Gnanaraj C; Ibrahim IAA; Shahzad N; Al-Ghamdi SS; Ayoub N; Veeraraghavan VP; Kumar SS; Esa NM; Arulselvan P
Biomed Pharmacother; 2018 Nov; 107():1514-1522. PubMed ID: 30257369
[TBL] [Abstract][Full Text] [Related]
38. KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.
Du L; Kim JJ; Shen J; Chen B; Dai N
Oncotarget; 2017 Mar; 8(13):22175-22186. PubMed ID: 28077799
[TBL] [Abstract][Full Text] [Related]
39. A Decade of Th9 Cells: Role of Th9 Cells in Inflammatory Bowel Disease.
Vyas SP; Goswami R
Front Immunol; 2018; 9():1139. PubMed ID: 29881387
[TBL] [Abstract][Full Text] [Related]
40. Colonic vitamin D metabolism: implications for the pathogenesis of inflammatory bowel disease and colorectal cancer.
Cross HS; Nittke T; Kallay E
Mol Cell Endocrinol; 2011 Dec; 347(1-2):70-9. PubMed ID: 21801808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
